Evidence map›Paper›PMID 40234391›Full record

ReviewNature communications2025

The road to commercial success for neuromorphic technologies.

Dylan Richard Muir, Sadique Sheik

Abstract readReview
In one paragraph

Review in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Closing the box.Cognitive neuroscience
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dylan Richard Muir *SynSense, Zürich, Switzerland. dylan.muir@synsense.ai.ORCID http://orcid.org/0000-0003-3856-826X
Sadique Sheik *SynSense, Zürich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromorphic technologies adapt biological neural principles to synthesise high-efficiency computational devices, characterised by continuous real-time operation and sparse event-based communication. After several false starts, a confluence of advances now promises widespread commercial adoption. Gradient-based training of deep spiking neural networks is now an off-the-shelf technique for building general-purpose Neuromorphic applications, with open-source tools underwritten by theoretical results. Analog and mixed-signal Neuromorphic circuit designs are being replaced by digital equivalents in newer devices, simplifying application deployment while maintaining computational benefits. Designs for in-memory computing are also approaching commercial maturity. Solving two key problems-how to program general Neuromorphic applications; and how to deploy them at scale-clears the way to commercial success of Neuromorphic processors. Ultra-low-power Neuromorphic technology will find a home in battery-powered systems, local compute for internet-of-things devices, and consumer wearables. Inspiration from uptake of tensor processors and GPUs can help the field overcome remaining hurdles.

Identifiers

PMID40234391
PMCPMC12000578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.